Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2013-01-10 Capital/Financing Update
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It reports changes in the company's outstanding share capital due to issuance of shares and warrants under a private placement and acquisition of royalty rights. The content focuses on capital raising activities and share issuance details, not on full financial results or management discussion. The document length is short (2433 characters) and it is a regulatory filing reporting capital structure changes. This fits the definition of a Capital/Financing Update (CAP) rather than a full annual or interim report or other categories.
2013-01-10 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a patent issuance and an update on a drug treatment. The document is short (2003 characters) and primarily serves as an announcement rather than a detailed financial or operational report. It does not contain comprehensive financial statements or detailed management discussion. According to the rules, Form 6-K filings that provide updates or announcements without substantive financial data are best classified under Regulatory Filings (RNS).
2013-01-07 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It mentions an upcoming presentation at healthcare conferences and provides a link to the presentation on the company's website. The document is short (1854 characters) and does not contain actual financial data or detailed report content. It primarily announces the availability of an investor presentation rather than providing the presentation itself. According to the rules, such announcements about presentations or reports being available online should be classified as Regulatory Filings (RNS) because it is a general regulatory announcement and does not contain substantive financial or report content.
2013-01-04 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release announcing the company's NASDAQ listing and commencement of trading under a ticker symbol. The document is short (1575 characters) and primarily serves as a regulatory announcement rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-12-27 English
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It reports on a special general meeting held on December 26, 2012, where shareholders approved a transaction involving the acquisition and termination of royalty rights in exchange for issuance of ordinary shares. It includes voting results and details about shares issued to directors. The document is short (2129 characters) and primarily announces the outcome of a shareholder vote and related share issuance. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a Proxy Solicitation or Voting Results announcement explicitly titled as such, but it does report voting results from a shareholder meeting. Given the nature of the content—shareholder vote results and share issuance related to a convertible loan agreement—the best fitting category is Declaration of Voting Results & Voting Rights Announcements (DVA). The confidence is high because the document explicitly states voting results and share issuance tied to the vote.
2012-12-27 English
Regulatory Filings 2012
Regulatory Filings
2012-12-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.